Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;32(4):e75.
doi: 10.3802/jgo.2021.32.e75.

Report from the 36th Annual Meeting of the Korean Society of Gynecologic Oncology (KSGO)

Ju Hyun Kim #  1 , Joseph J Noh #  2 , Kyung Jin Eoh #  3 , Young Tae Kim  4
Affiliations

Report from the 36th Annual Meeting of the Korean Society of Gynecologic Oncology (KSGO)

Ju Hyun Kim et al. J Gynecol Oncol. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. (A) Opening remark by Dr. Young Tae Kim, President of KSGO. (B) The main venue of the 36th Annual Meeting of KSGO.
KSGO, Korean Society of Gynecologic Oncology.
Fig. 2
Fig. 2. (A) Appreciation ceremony for the immediate past-president, Seung Cheol Kim and the (B) immediate past-secretary general, Dong Hoon Suh.
Fig. 3
Fig. 3. (A) Virtual lectures of Invited international speakers, Dr. Sudha Sundar from University of Birmingham, UK and (B) Dr. Bradly Monk from university of Arizona, USA.
Fig. 4
Fig. 4. Scenes from the Meeting of Korean Society of Gynecologic Oncology.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sundar SS, Leung E, Khan T, Glasbey J, Abu-Rustum N, Chiva LM, et al. 594 Impact of the covid pandemic on gynaecological cancer surgery – results from the covidsurg gynaecological cancer international study. Int J Gynecol Cancer. 2020;30:A123–4.
    1. Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European Society of Gynaecologic Oncology Quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer. 2016;26:1354–1363. - PubMed
    1. Bhattarai D, Singh S, Jang Y, Hyeon Han S, Lee K, Choi Y. An insight into drug repositioning for the development of novel anti-cancer drugs. Curr Top Med Chem. 2016;16:2156–2168. - PubMed
    1. Kobayashi Y, Kashima H, Rahmanto YS, Banno K, Yu Y, Matoba Y, et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget. 2017;8:72147–72156. - PMC - PubMed
    1. Kobayashi Y, Kashima H, Wu RC, Jung JG, Kuan JC, Gu J, et al. Mevalonate pathway antagonist suppresses formation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models. Clin Cancer Res. 2015;21:4652–4662. - PMC - PubMed

Publication types